Navigation Links
Lexicon Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
Date:9/6/2011

property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Lexicon Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
2. Lexicon Pharmaceuticals to Present at the Wedbush 2011 Life Sciences Management Access Conference
3. Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology
4. Phase 2 Trial of Lexicons LX1032, Telotristat Etiprate, Shows Positive Results in Carcinoid Syndrome
5. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 Second Quarter Results
6. Lexicons IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
7. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
8. Lexicon Pharmaceuticals Announces Webcast of 2011 Annual R&D Day
9. Lexicon Pharmaceuticals Reports on Clinical Program Status and 2011 First Quarter Results
10. Lexicon to Provide First Quarter 2011 Financial Results
11. Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... NEW YORK , September 22, 2014 ... New Market Report on "Global Market Study on Ophthalmic ... Growth by 2020," the global ophthalmic devices market was valued at ... grow at a CAGR of 6.5% from 2014 to ... million in 2020. Browse the full Global Market ...
(Date:9/22/2014)...  Neuralstem, Inc. (NYSE MKT: CUR) announced that ... University, presented long-term follow up data on the Phase ... the treatment of amyotrophic lateral sclerosis (ALS or ... the Annual Symposium on ALS of the Foundation Andre-Delambre, ... and was not open to the public, covered data ...
(Date:9/22/2014)... PHOENIX , Sept. 22, 2014  For ... wrists, surgery often means facing the prospect of ... can be imagined, regular activities are also impacted, ... on the severity of the problem, some patients ... braces, which can even lead to permanent damage ...
Breaking Medicine Technology:Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 2Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 3Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 4Global Ophthalmic Devices Market will Reach $2,685.1 Million in 2020: Persistence Market Research 5Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4Phoenix Arizona Hand Doctor Develops Revolutionary New Surgery System, Eliminates Need for Large Incisions 2
... (Nasdaq: BMRN ) today announced that Joshua Grass, ... a company update at the UBS Global Life Sciences Conference ... 3:30 p.m. ET.   Interested parties may access ... investor section of the BioMarin website, www.BMRN.com .  A ...
... Arcion Therapeutics , a venture backed clinical stage ... announced that the U.S. Food and Drug Administration (FDA) ... treatment of pain associated with Painful Diabetic Neuropathy (PDN). ... for topical administration. Arcion recently announced positive ...
Cached Medicine Technology:BioMarin to Present at the UBS Global Life Sciences Conference 2Arcion Therapeutics Receives FDA Fast Track Designation for ARC-4558 for the Treatment of Pain Associated with Painful Diabetic Neuropathy 2
(Date:9/22/2014)... 2014 -- Recent two-generation approaches to reducing poverty ... increasing attention from researchers, advocates, and foundations. By ... them to move to jobs that offer a ... and education for children, these programs aim to ... according to a new report from the National ...
(Date:9/22/2014)... 2014. Kessler researchers have published a pilot study ... program in people with multiple sclerosis (MS). ... perceived stress, and pain. "Development and effectiveness ... with MS: Description and outcomes" was epublished ahead ... International Journal of MS Care (doi: 10.7224/1537-2073.2013-045). ...
(Date:9/22/2014)... 22, 2014 The Workgroup ... leading nonprofit authority on the use of health ... announced findings from its recent industry survey on ... (HPID) within electronic transactions adopted under the Health ... the survey from August 20 to September 5, ...
(Date:9/22/2014)... MONDAY, Sept. 22, 2014 (HealthDay News) -- Scans ... they learn to read. This finding could potentially ... other reading difficulties early on, preliminary research suggests. ... in children with dyslexia as well as most ... Hoeft, an associate professor of child and adolescent ...
(Date:9/22/2014)... Barbara Bronson Gray HealthDay ... It,s something every pregnant woman wonders: What can I do ... that taking iron supplements as prescribed may play a role ... spectrum disorder (ASD). The researchers found that mothers of ... iron supplements before and during pregnancy than those whose children ...
Breaking Medicine News(10 mins):Health News:A two-generation lens: Current state policies fail to support families with young children 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 2Health News:WEDI Announces Survey Results from Unique Health Plan Identifier (HPID) Industry Poll 3Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 2Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 3
... Centers for,Medicare & Medicaid Services (CMS) has selected the ... data analysis,services to detect potential fraud and waste in ... task order to help identify inappropriate,and unnecessary Medicaid payments ... MIP was created as a result of the federal ...
... MED, CEO DeCODE Genetics, WASHINGTON, June 5 ... Cardiovascular Institute:, Date: Thursday, June 12, 2008, ... 23rd Street, NW, Time: Noon - 2:50pm, ... Dr. Stefansson is CEO and co-founder of deCODE genetics ...
... MA Researchers from Boston University School of Medicine (BUSM) ... among Medicare beneficiaries at the end of life. The ... Internal Medicine. , According to researchers, medical treatments for ... year comprise almost 30 percent of Medicare expenditures. In ...
... Visit Denver to Rally Residents to Eat Right, Move More and ... Milk ... by the,ups and downs of different fad diets -- which seem to go ... been,slim. Two out of three Americans remain overweight or obese., A new ...
... and Indiana Fever for an evening of celebration, INDIANAPOLIS, ... will be honored by the March of Dimes on June ... collaboration to help families,with critically ill babies throughout the state ... walk., For several years, Anthem has teamed up with ...
... enable sexual maturity and fertility make a critical journey: from ... the brain. , They believe their studies in the ... neurons don,t make it and enable better ways to help ... "They can go to the right place but take too ...
Cached Medicine News:Health News:CMS Selects Thomson Reuters to Help Detect Medicaid Fraud in Eight States 2Health News:Genomics of Cardiovascular Disease: Current Clinical Applications 2Health News:Primary care visits reduce hospital utilization among Medicare beneficiaries at the end of life 2Health News:Message to Denver Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Denver Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:Message to Denver Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 4Health News:Anthem Blue Cross and Blue Shield Honored by March of Dimes 2Health News:Zebrafish enable scientists to study the migration of neurons that enable sexual maturity 2Health News:Zebrafish enable scientists to study the migration of neurons that enable sexual maturity 3
... For enzyme immunoassays, designed to meet the ... and allows the user to run set ... The floating manifold on this strip washer ... at a time. Reliable, compact, and self-contained, ...
... available to handle multiple assays: ... Embla 384 Cell washer has ... optimized to avoid cell disturbance. ... and have been integrated with ...
... miniGene LW is a new plate washing system ... and 384 channel microplates with flat, V-shaped or ... 8 or 16 channel nozzle heads. Simple LCD ... An optional plate stacker is available for the ...
Space-saving counter top model,User initiated manual defrost,Standard features (see above),Internal freezing compartment,Removable half-shelf in refrigerator,Two shelves in door,UL 471 Commercial Ref...
Medicine Products: